Abstract: The technology disclosed relates to determining feasibility of using a reference genome of a non-target species for variant calling a sample of a target species. In particular, the technology disclosed relates to mapping sequenced reads of a sample of a target species to a reference genome of a non-target species to detect a first set of variants in the sequenced reads of the sample of the target species, and mapping the sequenced reads of the sample of the target species to a reference genome of a pseudo-target species to detect a second set of variants in the sequenced reads of the sample of the target species.

Abstract: A computer-implemented method of quantifying a strength of association of genes associated with a phenotype and a contribution of rare variants to a phenotype response by calculating a weighted burden score for a plurality of associated genes with a specified phenotype, wherein the burden score identifies identifying consequential, non-random association in a cohort between carrier status of each of the associated genes and a phenotype response to presence in the associated genes of one or more rare pathogenic variants. Respective effective strength scores are determined for the consequential, non-random association for genes selected from the associated genes based on respective burden scores at per-gene resolution.

Abstract: The technology disclosed relates to generating species-differentiable evolutionary profiles using a weighting logic. In particular, the technology disclosed relates to determining a weighted summary statistic for a given residue category at a given position in a multiple sequence alignment based on one or more weights of one or more sequences in the multiple sequence alignment that have a residue of the given residue category at the given position.

Abstract: The technology disclosed relates to a system for inter-model prediction score recalibration. The system includes a first model that generates, based on evolutionary conservation summary statistics of amino acids in a reference protein sequence, a first set of pathogenicity scores with rankings for variants that mutate the reference sequence to alternate protein sequences. The system further includes a second model that generates, based on epistasis expressed by amino acid patterns spanning a multiple sequence alignment aligning the reference sequence to non-target sequences, a second set of pathogenicity scores with rankings for the variants. The system further includes a rank loss determination logic that determines a rank loss parameter by comparing the two sets of rankings, a loss function reconfiguration logic that reconfigures a loss function based on the rank loss parameter, and a training logic that uses the reconfigured loss function to train the first model.

Abstract: A computer-implemented method of predicting phenotypic shift in response to usage of a plurality of drugs on a plurality of phenotypes of a cohort of individuals with a plurality of confounders. The cohort of individuals has associated phenotype measurements, covariate measurements, and drug usage patterns for two separate time points. The phenotype measurements for the first and second time points are covariate-corrected and drug-usage corrected through the use of biostatistics.

Abstract: The technology disclosed relates to training a pathogenicity predictor.

Abstract: The technology disclosed relates to determining pathogenicity of nucleotide variants. In particular, the technology disclosed relates to specifying a particular amino acid at a particular position in a protein as a gap amino acid, and specifying remaining amino acids at remaining positions in the protein as non-gap amino acids, generating a gapped spatial representation of the protein that includes spatial configurations of the non-gap amino acids, and excludes a spatial configuration of the gap amino acid, determining an evolutionary conservation at the particular position of respective amino acids of respective amino acid classes based at least in part on the gapped spatial representation, and based at least in part on the evolutionary conservation of the respective amino acids, determining a pathogenicity of respective nucleotide variants that respectively substitute the particular amino acid with the respective amino acids in alternate representations of the protein.

Abstract: The technology disclosed relates to constructing a convolutional neural network-based classifier for variant classification. In particular, it relates to training a convolutional neural network-based classifier on training data using a backpropagation-based gradient update technique that progressively match outputs of the convolutional network network-based classifier with corresponding ground truth labels. The convolutional neural network-based classifier comprises groups of residual blocks, each group of residual blocks is parameterized by a number of convolution filters in the residual blocks, a convolution window size of the residual blocks, and an atrous convolution rate of the residual blocks, the size of convolution window varies between groups of residual blocks, the atrous convolution rate varies between groups of residual blocks. The training data includes benign training examples and pathogenic training examples of translated sequence pairs generated from benign variants and pathogenic variants.

Abstract: The technology disclosed describes determination of which elements of a sequence are nearest to uniformly spaced cells in a grid, where the elements have element coordinates, and the cells have dimension-wise cell indices and cell coordinates. The determination includes generating an element-to-cells mapping that maps, to each of the elements, a subset of the cells. The subset of the cells mapped to a particular element in the sequence includes a nearest cell in the grid and one or more neighborhood cells in the grid, and the nearest cell is selected based on matching element coordinates of the particular element to the cell coordinates. The determination further includes generating a cell-to-elements mapping that maps, to each of the cells, a subset of the elements, and using the cell-to-elements mapping to determine, for each of the cells, a nearest element in the sequence.

Abstract: The technology disclosed relates to a variant pathogenicity prediction network. The variant pathogenicity classifier includes memory, a variant encoding sub-network, a protein contact map generation sub-network, and a pathogenicity scoring sub-network. The memory stores a reference amino acid sequence of a protein, and an alternative amino acid sequence of the protein that contains a variant amino acid caused by a variant nucleotide. The variant encoding sub-network is configured to process the alternative amino acid sequence, and generate a processed representation of the alternative amino acid sequence. The protein contact map generation sub-network is configured to process the reference amino acid sequence and the processed representation of the alternative amino acid sequence, and generate a protein contact map of the protein. The pathogenicity scoring sub-network is configured to process the protein contact map, and generate a pathogenicity indication of the variant amino acid.

Abstract: The technology disclosed relates to a variant pathogenicity classifier. The variant pathogenicity classifier comprises memory and runtime logic. The memory stores (i) a reference amino acid sequence of a protein, (ii) an alternative amino acid sequence of the protein that contains a variant amino acid caused by a variant nucleotide, and (iii) a protein contact map of the protein. The runtime logic has access to the memory, and is configured to provide (i) the reference amino acid sequence, (ii) the alternative amino acid sequence, and (iii) the protein contact map as input to a first neural network, and to cause the first neural network to generate a pathogenicity indication of the variant amino acid as output in response to processing (i) the reference amino acid sequence, (ii) the alternative amino acid sequence, and (iii) the protein contact map.

Abstract: The technology disclosed relates to determining pathogenicity of nucleotide variants. In particular, the technology disclosed relates to specifying a particular amino acid at a particular position in a protein as a gap amino acid, and specifying remaining amino acids at remaining positions in the protein as non-gap amino acids. The technology disclosed further relates to generating a gapped spatial representation of the protein that includes spatial configurations of the non-gap amino acids, and excludes a spatial configuration of the gap amino acid, and determining a pathogenicity of a nucleotide variant based at least in part on the gapped spatial representation, and a representation of an alternate amino acid created by the nucleotide variant at the particular position.

Abstract: An artificial intelligence-based system comprises an input preparation module that accesses a sequence database and generates an input base sequence. The input base sequence comprises a target base sequence with target bases, wherein the target base sequence is flanked by a right base sequence with downstream context bases, and a left base sequence with upstream context bases. A sequence-to-sequence model processes the input base sequence and generates an alternative representation of the input base sequence. An output module processes the alternative representation of the input base sequence and produces at least one per-base output for each of the target bases in the target base sequence. The per-base output specifies, for a corresponding target base, signal levels of a plurality of epigenetic tracks.

Abstract: The technology disclosed relates to determining pathogenicity of variants. In particular, the technology disclosed relates to generating amino acid-wise distance channels for a plurality of amino acids in a protein. Each of the amino acid-wise distance channels has voxel-wise distance values for voxels in a plurality of voxels. A tensor includes the amino acid-wise distance channels and at least an alternative allele of the protein expressed by a variant. A deep convolutional neural network determines a pathogenicity of the variant based at least in part on processing the tensor. The technology disclosed further augments the tensor with supplemental information like a reference allele of the protein, evolutionary conservation data about the protein, annotation data about the protein, and structure confidence data about the protein.

Abstract: The technology disclosed relates to constructing a convolutional neural network-based classifier for variant classification. In particular, it relates to training a convolutional neural network-based classifier on training data using a backpropagation-based gradient update technique that progressively match outputs of the convolutional neural network-based classifier with corresponding ground truth labels. The convolutional neural network-based classifier comprises groups of residual blocks, each group of residual blocks is parameterized by a number of convolution filters in the residual blocks, a convolution window size of the residual blocks, and an atrous convolution rate of the residual blocks, the size of convolution window varies between groups of residual blocks, the atrous convolution rate varies between groups of residual blocks. The training data includes benign training examples and pathogenic training examples of translated sequence pairs generated from benign variants and pathogenic variants.

Abstract: The technology disclosed relates to determining pathogenicity of variants. In particular, the technology disclosed relates to generating amino acid-wise distance channels for a plurality of amino acids in a protein. Each of the amino acid-wise distance channels has voxel-wise distance values for voxels in a plurality of voxels. A tensor includes the amino acid-wise distance channels and at least an alternative allele of the protein expressed by a variant. A deep convolutional neural network determines a pathogenicity of the variant based at least in part on processing the tensor. The technology disclosed further augments the tensor with supplemental information like a reference allele of the protein, evolutionary conservation data about the protein, annotation data about the protein, and structure confidence data about the protein.

Abstract: A system includes at least a voxelizer, an alternative allele encoder, an evolutionary conservation encoder, and a convolutional neural network. The voxelizer accesses a three-dimensional structure of a reference amino acid sequence of a protein and fits a three-dimensional grid of voxels on atoms in the three-dimensional structure on an amino acid-basis to generate amino acid-wise distance channels. The alternative allele encoder encodes an alternative allele sequence to each voxel in the three-dimensional grid of voxels. The evolutionary conservation encoder encodes an evolutionary conservation sequence to each voxel in the three-dimensional grid of voxels. The convolutional neural network applies three-dimensional convolutions to a tensor that includes the amino acid-wise distance channels encoded with the alternative allele sequence and respective evolutionary conservation sequences and determines a pathogenicity of a variant nucleotide based at least in part on the tensor.

Abstract: The technology disclosed relates to determining pathogenicity of variants. In particular, the technology disclosed relates to generating amino acid-wise distance channels for a plurality of amino acids in a protein. Each of the amino acid-wise distance channels has voxel-wise distance values for voxels in a plurality of voxels. A tensor includes the amino acid-wise distance channels and at least an alternative allele of the protein expressed by a variant. A deep convolutional neural network determines a pathogenicity of the variant based at least in part on processing the tensor. The technology disclosed further augments the tensor with supplemental information like a reference allele of the protein, evolutionary conservation data about the protein, annotation data about the protein, and structure confidence data about the protein.

Abstract: The technology disclosed relates to efficiently determining which atoms in a protein are nearest to voxels in a grid. The atoms have three-dimensional (3D) atom coordinates, and the voxels have 3D voxel coordinates. The technology disclosed generates an atom-to-voxels mapping that maps, to each of the atoms, a containing voxel selected based on matching 3D atom coordinates of a particular atom of the protein to the 3D voxel coordinates in the grid. The technology disclosed generates a voxel-to-atoms mapping that maps, to each of the voxels, a subset of the atoms. The subset of the atoms mapped to a particular voxel in the grid includes those atoms in the protein that are mapped to the particular voxel by the atom-to-voxels mapping. The technology disclosed includes using the voxel-to-atoms mapping to determine, for each of the voxels, a nearest atom in the protein.

Abstract: The technology disclosed relates to constructing a computer-implemented method for variant classification. In particular, the method includes using a pathogenicity prediction neural network to process as input, (i) a reference protein sequence that has a first chain of amino acids with at least twenty amino acids, (ii) an alternative protein sequence aligned with the reference sequence, where the alternative protein sequence has a second chain of amino acids with at least twenty amino acids, and the first and second chains of amino acids differ by a variant amino acid caused by a nucleotide substitution, and (iii) a primate conservation profile generated using a primate cross-species multiple sequence alignment that aligns the reference protein sequence with other protein sequences from primate species. The method further includes based on the processing of the input by the neural network, generating as output a pathogenicity prediction for the nucleotide substitution.